Literature DB >> 18188517

Helical tomotherapy. Experiences of the first 150 patients in Heidelberg.

Florian Sterzing1, Kai Schubert, Gabriele Sroka-Perez, Jörn Kalz, Jürgen Debus, Klaus Herfarth.   

Abstract

BACKGROUND AND
PURPOSE: Helical tomotherapy was introduced into clinical routine at the Department of Radiation Oncology, University Hospital of Heidelberg, Germany, in July 2006. This report is intended to describe the experience with the first 150 patients treated with helical tomotherapy. Patient selection, time effort, handling of daily image guidance with megavoltage (MV) CT, and quality of radiation plans shall be assessed. PATIENTS AND METHODS: Between July 2006 and May 2007, 150 patients were treated with helical tomotherapy in the University Hospital of Heidelberg. Mean age was 60 years with a minimum of 30 years and a maximum of 85 years. 79 of these patients received radiotherapy as a part of multimodal treatment pre- or postoperatively, 17 patients received treatment as a combined radiochemotherapy. 76% were treated with curative intent. Radiotherapy sites were central nervous system (n = 7), head and neck (n = 28), thoracic (n = 37), abdominal (n = 58) and skeletal system (n = 20). Most common tumor entities were prostate cancer (n = 28), breast cancer (n = 17), gastrointestinal tumors (n = 19), pharyngeal carcinoma (n = 14), lymphoma (n = 13), metastatic disease (bone n = 14, liver n = 6, lung n = 4, lymph node n = 2), sarcoma (n = 8), malignant pleural mesothelioma (n = 5), ovarian cancer treated with whole abdominal irradiation (n = 4), lung cancer (n = 3), skin malignancies (n = 3), chordoma (n = 2), meningioma (n = 2), one ependymoma and one medulloblastoma treated with craniospinal axis irradiation (n = 2), and others (n = 4). Nine patients were treated with single-fraction radiosurgery, nine with image-guided spinal reirradiation, and twelve patients were treated at multiple targets simultaneously. A pretreatment MV-CT scan was performed in 98.2% of the 3,026 fractions applied. After matching with the kilovoltage planning CT, corrections for translations and rotation around longitudinal axis (roll) were done.
RESULTS: Mean time on table was 24.8 min for the mentioned tumor entities with fractionated radiation, mean treatment time 10.7 min. Mean correction vector after MV-CT registration was 6.9 mm. With helical tomotherapy it was possible to achieve highly conformal dose distributions for targets of all sizes and multiple targets within one procedure. Image guidance with MV-CT allowed daily position correction and safe and precise treatment application. This was feasible even if the desired immobilization was not possible due to obesity, claustrophobia, pain, or neurologic or orthopedic impairment.
CONCLUSION: Helical tomotherapy and daily image guidance with MV-CT could fast be introduced into daily clinical routine. This technique allows precise intensity-modulated radiotherapy (IMRT) in standard cases and offers new treatment options in a huge variety of difficult cases.

Entities:  

Mesh:

Year:  2008        PMID: 18188517     DOI: 10.1007/s00066-008-1778-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  63 in total

1.  Computed tomography as a source of electron density information for radiation treatment planning.

Authors:  Witold Skrzyński; Sylwia Zielińska-Dabrowska; Marta Wachowicz; Wioletta Slusarczyk-Kacprzyk; Paweł F Kukołowicz; Wojciech Bulski
Journal:  Strahlenther Onkol       Date:  2010-05-17       Impact factor: 3.621

2.  Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.

Authors:  S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

3.  Quality Control of Portal Imaging with PTW EPID QC PHANTOM.

Authors:  Csilla Pesznyák; Gábor Fekete; Arpád Mózes; Balázs Kiss; Réka Király; István Polgár; Pál Zaránd; Arpád Mayer
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

Review 4.  Nodal follicular lymphoma: the role of radiotherapy for stages I and II.

Authors:  Frank Heinzelmann; Marianne Engelhard; Hellmut Ottinger; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

5.  Postoperative radiotherapy for advanced prostate cancer: improved local control translates into increased survival.

Authors:  Marie-Luise Sautter-Bihl; Felix Sedlmayer; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

Review 6.  [What is the impact of new radiotherapy techniques?].

Authors:  F Sterzing; M W Münter; A D Jensen; E M Stoiber; P Huber; K K Herfarth; J Debus
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

7.  Quality of patient positioning during cerebral tomotherapy irradiation using different mask systems.

Authors:  C Leitzen; T Wilhelm-Buchstab; S Garbe; C Lütter; T Müdder; B Simon; H H Schild; H Schüller
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

8.  The value of image-guided intensity-modulated radiotherapy in challenging clinical settings.

Authors:  S J Treece; M Mukesh; Y L Rimmer; S J Tudor; J C Dean; R J Benson; D L Gregory; G Horan; S J Jefferies; S G Russell; M V Williams; C B Wilson; N G Burnet
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

9.  Technical considerations for noncoplanar proton-beam therapy of patients with tumors proximal to the optic nerve.

Authors:  Masashi Mizumoto; Hidetsugu Nakayama; Mari Tokita; Shinji Sugahara; Haruko Hashii; Takeji Sakae; Koji Tsuboi; Hideyuki Sakurai; Koichi Tokuuye
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

10.  Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines.

Authors:  Ina Patties; Jutta Jahns; Guido Hildebrandt; Rolf-Dieter Kortmann; Annegret Glasow
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.